76 pharmaceutical companies pre-hi performance throughout the year

Pharmaceutical Network December 14, the pharmaceutical sector overall good profit throughout the year.Wind data show that the disclosure of the annual performance notice of the 90 pharmaceutical companies, 76 pre-hi, pre-hi ratio as high as 84.44%, of which a slight increase of 44 , Turnaround 2, continued surplus 13, pre-17; net profit of more than 1 billion companies 8, 1-10 billion 48 companies.

Product price increase is medicine An important factor in the growth performance of listed companies.Efanfan is expected to achieve annual net profit of 1.133 billion yuan -13.74 billion yuan, an increase of 65% -95%, mainly due to vitamin B5 and other products a larger increase in prices. (002365, Shares) expects net profit up 160% -210%, mainly due to taurine sales prices, sales revenue and gross margin increased.

Policy support is also a major factor health For example, the company expects to achieve annual net profit attributable to shareholders of listed companies 550 million -650 million, an increase of 62.28% -91.79%. The company said that thanks to 'healthy China' supportive policies have been landing one after another, the public health Consumption upgrade, the health examination industry entered a period of rapid development, the market demand.Company bigger and stronger physical examination main business, while consolidating the advantages of first and second tier cities, increase the layout of third and fourth tier cities, the scale and brand highlights.

The acquisition of subsidiaries consolidated the performance of some companies to promote growth to Health Hong Medical (002219, Shares), for example, the company expects to achieve net profit attributable to shareholders of listed companies 420 million -49 million, an increase of 4.06% -21.4% During the period, the Company completed the delivery of the 70% equity interest in PRP Diagnostic Imaging Pty Ltd and expanded the scope of consolidated statements. Meanwhile, hospital Management efficiency to further improve.

By the government subsidies to reduce R & D costs increase, the adjustment of the health insurance directory, part of the company's performance decline.Union Yuheng Pharmaceutical (002437, Shares), for example, the company expects to achieve attributable to shareholders of listed companies net profit of 287 million -43 million , Down 40% -60% .Company said that by two-vote policy to promote the impact of the company gradually adjust the existing sales channels, delivery reduced; part of the sales of products affected by health insurance directory adjustment.

Since December, many state-owned pharmaceutical companies such as Shinbun Pharmaceutical Co., Ltd. and Yi Bai Pharmaceutical Co., Ltd. have issued share repurchase plans and repurchased their own shares with their own funds to reduce their registered capital, such as Yi Bai Pharma, which plans to repurchase a total amount of 200 million yuan , Repurchase price does not exceed 13 yuan / share.

According to insiders, the repurchase by listed companies can play a role in stabilizing the market and restoring investor confidence, and at the same time, it conveys the signal that the company believes its stock price is undervalued.

Health Heart Dong Zhigao executives terminate the plan to reduce the company said the original plan to reduce the funds through other channels have been resolved, based on the confidence of the company's future development, decided to early termination plan.

Insiders said the medical index experienced a roller coaster market, the basic drop back to the end of September point, in a number of positive factors under the resonance, the pharmaceutical sector deserve attention.

Southwest Securities analyst Zhu Guoguang Pharmaceutical China Securities Journal said that in 2018 the pharmaceutical industry ideas can be divided into four points: the new era of medicine into the 3.0, more obvious benefits of innovative drugs; consistency assessment into the harvest period, drug Supply-side reform leads a good company; consumption upgrade and high-end consumption, promote the continued growth of brand demand for Chinese medicine; medical reform policy to support the community to do medical services, private medical services business high-speed heavy volume.